CFO4Life Group LLC Buys 34 Shares of Eli Lilly and Company (NYSE:LLY)

CFO4Life Group LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 3.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,040 shares of the company’s stock after purchasing an additional 34 shares during the quarter. CFO4Life Group LLC’s holdings in Eli Lilly and Company were worth $803,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of LLY. Principal Financial Group Inc. grew its position in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after purchasing an additional 60,306 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $606,000. Carrera Capital Advisors acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $244,000. Moser Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 40.0% in the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock valued at $403,000 after purchasing an additional 130 shares during the period. Finally, Empower Advisory Group LLC grew its position in shares of Eli Lilly and Company by 4.3% in the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock valued at $123,388,000 after purchasing an additional 5,682 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 0.2 %

Shares of Eli Lilly and Company stock opened at $822.26 on Thursday. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The stock has a market cap of $779.64 billion, a P/E ratio of 70.22, a P/E/G ratio of 1.40 and a beta of 0.34. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business’s 50 day moving average is $829.78 and its 200-day moving average is $845.29.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its board has authorized a share repurchase plan on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

LLY has been the subject of a number of recent research reports. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research report on Friday, January 17th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Wells Fargo & Company upped their price target on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.